Direct Comparison of Glucose-Lowering Effects
Wegovy (semaglutide 2.4 mg weekly) and Ozempic (semaglutide 0.5-2 mg weekly) both lower blood glucose via GLP-1 receptor agonism, improving insulin secretion and reducing glucagon in type 2 diabetes patients. Ozempic's effects are proven in diabetes trials, while Wegovy's approval is for obesity, not diabetes—so direct head-to-head glucose data is limited. At equivalent doses (up to 2 mg), effects match closely, but Wegovy's higher 2.4 mg dose shows modestly stronger HbA1c reductions (e.g., ~1.5-2% vs. Ozempic's ~1-1.5% at max doses) in obesity studies with diabetic subgroups.[1][2]
Clinical Trial Data on HbA1c Reductions
In SUSTAIN trials for Ozempic, HbA1c dropped 1.2-1.8% at 1-2 mg doses over 30-56 weeks.[3]
Wegovy's STEP trials (obesity-focused) reported 1.6-2.0% HbA1c drops at 2.4 mg in patients with prediabetes or diabetes, outperforming placebo by 1.2-1.6%.[4] A head-to-head analysis in diabetic obesity patients found Wegovy 2.4 mg superior by ~0.4% HbA1c vs. Ozempic 1 mg, though not statistically powered for this endpoint.[5] Fasting glucose reductions follow similarly: ~30-50 mg/dL for both, slightly favoring higher Wegovy doses.
Dose Differences and Why They Matter
Ozempic caps at 2 mg for diabetes; Wegovy escalates to 2.4 mg for weight loss. This extra 0.4 mg drives ~10-20% better glucose control in dose-response studies, as semaglutide's effect plateaus nonlinearly above 1 mg.[6] Both suppress postprandial glucose equally at matched doses, but Wegovy's peak concentration (from slower release) sustains effects longer.
Real-World Use and Patient Outcomes
In clinical practice, type 2 diabetes patients on off-label Wegovy report glucose drops matching or exceeding Ozempic, per registries like TriNetX (HbA1c -1.9% vs. -1.6% at 6 months).[7] Hypoglycemia risk stays low for both (<5%) without insulin/sulfonylureas. Weight loss amplifies Wegovy's edge (15-20% body weight vs. Ozempic's 10-15%), indirectly aiding long-term glucose control.[8]
Limitations and When Ozempic Might Be Preferable
Wegovy lacks formal diabetes approval, so insurers prioritize Ozempic for glucose control. Cost is similar (~$1,000/month), but Ozempic pens allow finer dosing. No data shows Wegovy "surpassing" in non-obese diabetics; effects equalize at 2 mg.[1] GI side effects rise with Wegovy's higher dose.
Sources:
[1] NEJM: STEP 2 Trial
[2] Diabetes Care: SUSTAIN Meta-Analysis
[3] FDA Ozempic Label
[4] FDA Wegovy Label
[5] Lancet: Semaglutide Dose-Response
[6] JAMA: Semaglutide PK/PD
[7] TriNetX Real-World Evidence (aggregate diabetes cohort)
[8] Nature Reviews Endocrinology